CYP2D6 and breast carcinoma: Our findings indicate that more work is needed to clarify the impact of CYP2D6 activity on adherence to tamoxifen, and whether individualized dosing of tamoxifen based on CYP2D6 genotype, aiming at improving patients’ quality of life and adherence, might further decrease the risk of recurrence and breast cancer mortality.